Citrin D L, Kies M S, Wallemark C B, Khandekar J, Kaplan E, Camacho F, Lind R
Cancer. 1985 Aug 1;56(3):457-60. doi: 10.1002/1097-0142(19850801)56:3<457::aid-cncr2820560307>3.0.co;2-7.
Twenty-five patients with metastatic prostate cancer resistant to primary hormone therapy, received high-dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES-P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high-dose Stilphostrol in the treatment of hormone-resistant prostate cancer is limited.
